Pharmacogenomics in the treatment of epilepsy

Colleen E Clancy, Robert S. Kass

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Genetic variability has recently been implicated in the development of familial epilepsy syndromes and in heterogeneous responses of epilepsy patients to drug treatment. Mutations in distinct proteins have been shown to underlie the development of epilepsy, increase propensity for drug resistance, and alter drug metabolism. Improved understanding of how individual genetic variability may alter the efficacy of pharmacological therapeutic interventions is an important and timely goal. The investigation of relationships between genotype and patient responses to drug treatment is termed pharmacogenomics.

Original languageEnglish (US)
Pages (from-to)747-751
Number of pages5
Issue number6
StatePublished - Nov 2003
Externally publishedYes


  • Epilepsy
  • Mutations
  • Pharmacogenetics
  • Pharmacogenomics
  • Pharmacology
  • Polymorphisms

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)


Dive into the research topics of 'Pharmacogenomics in the treatment of epilepsy'. Together they form a unique fingerprint.

Cite this